Key result
Zofenopril, an angiotensin-converting enzyme inhibitor, is effective and safe for the treatment of combined cardiovascular disease.
This review highlights the efficacy and safety of zofenopril, an ACE inhibitor with a sulfhydryl group, in patients with cardiovascular disease.
Supports zofenopril consideration in combined CVD but should not yet change practice; leaves open need for dedicated RCTs.
Hyperactivity of the renin-angiotensin-aldosterone system plays an important role in the pathogenesis of any cardiovascular disease. Angiotensin - converting enzyme inhibitors are the main drugs among many medicines influencing the activity of the renin-angiotensin-aldosterone system, and these inhibitors have a wide range of beneficial effects. The presence of the sulfhydryl group in a molecule of angiotensin-converting enzyme inhibitor (zofenopril) determines the number of unique properties of this drug. Recent results have been showing the effectiveness of treatment in case of combined cardiovascular disease. This article presents the results of the studies showing the efficacy and safety of zofenopril.
No takes yet. Share an insight, caveat, or question.
Kukes et al. (2014) conducted a review in cardiovascular disease. zofenopril was evaluated. Zofenopril, an angiotensin-converting enzyme inhibitor, is effective and safe for the treatment of combined cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: